Zentalis Pharmaceuticals, Inc.
zentalis.comWhat Do They Do?
Develops azenosertib, an investigational cancer medicine for patients with ovarian cancer and other tumor types, with its current clinical focus on biomarker-selected platinum-resistant ovarian cancer.
10-K for FY2025, filed Mar 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$42.3MView ↗
- ▲ +57% (Loss)
- vs −$26.9M in Q2 FY2025
-
Aug 14, 2026
Zentalis priced a common-stock offering
The company agreed to sell 23,000,000 shares at $3.50 each and estimated net proceeds of approximately $75.1 million.
Sources
8-K, filed Aug 14, 2026
On August 13, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”)…View ↗
-
Aug 6, 2026
DENALI Part 2 topline readout moved to the first half of 2027
The company said Part 2c is enrolling and the integrated readout is expected after full enrollment and data maturation.
Sources
8-K, filed Aug 6, 2026
Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2 Enrollment completed in…View ↗
Narrower development pipeline
The earlier report described cancer-drug candidates, a protein degrader and research on undisclosed targets. The latest report centers on azenosertib for biomarker-selected platinum-resistant ovarian cancer and a combination study in ovarian cancer.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Mar 26, 2026We are a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental…View ↗
Azenosertib (ZN-c3), a potentially first-in-class Wee1 inhibitor for advanced solid tumors and hematological malignancies; ZN-d5, a B-cell…View ↗
We are currently evaluating azenosertib and ZN-d5 in multiple ongoing clinical trials and conducting studies to enable an Investigational…View ↗
We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and…View ↗
Rapidly advance the clinical development of azenosertib as a monotherapy toward first regulatory approval in Cyclin E1-positive PROC. We…View ↗
Monotherapy – Phase 2 Clinical Trial in PROC (DENALI - ZN-c3-005). DENALI Part 1b is a single-arm study that evaluated azenosertib…View ↗
Who Do They Compete With?
Competes with Debiopharm Research & Manufacturing SA, Bristol-Myers Squibb, Aprea Therapeutics, Schrödinger, Acrivon Therapeutics, Impact Therapeutics, Shouyao Holdings, WuXi AppTec, and Wigen Biomedicine Technology (Shanghai)
10-K for FY2025, filed Mar 26, 2026Currently, there are no WEE1 inhibitors approved by the FDA. Debiopharm Research & Manufacturing SA has disclosed that it is clinically…View ↗
Loading...
